G, Q. A., M, S., S, C., JC, M., M, J., M, R., . . . R, L. (2020). First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: Results of a phase II trial. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 22(4), 495. https://doi.org/10.1007/s12094-019-02151-6
Chicago Style (17th ed.) CitationG, Quintero Aldana, et al. "First-line Panitumumab Plus Docetaxel and Cisplatin in Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma: Results of a Phase II Trial." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 22, no. 4 (2020): 495. https://doi.org/10.1007/s12094-019-02151-6.
MLA (9th ed.) CitationG, Quintero Aldana, et al. "First-line Panitumumab Plus Docetaxel and Cisplatin in Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma: Results of a Phase II Trial." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 22, no. 4, 2020, p. 495, https://doi.org/10.1007/s12094-019-02151-6.
